| pubmed-article:1954180 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1954180 | lifeskim:mentions | umls-concept:C1880904 | lld:lifeskim |
| pubmed-article:1954180 | lifeskim:mentions | umls-concept:C0001418 | lld:lifeskim |
| pubmed-article:1954180 | lifeskim:mentions | umls-concept:C0055633 | lld:lifeskim |
| pubmed-article:1954180 | lifeskim:mentions | umls-concept:C2709248 | lld:lifeskim |
| pubmed-article:1954180 | lifeskim:mentions | umls-concept:C0205462 | lld:lifeskim |
| pubmed-article:1954180 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:1954180 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1954180 | pubmed:dateCreated | 1991-12-30 | lld:pubmed |
| pubmed-article:1954180 | pubmed:abstractText | One hundred-fourteen patients with inoperable adenocarcinoma of the lung (ACL) were evaluated by immunohistochemistry with monoclonal antibodies against Neuron Specific Enolase (NSE) and Chromogranin A (Chr A) in order to determine the frequency and prognostic impact of such antigen expression. All patients were previously untreated and received chemotherapy according to a prospective randomized trial. The tumors of 18 patients (16%) had more than 10% positive cells stained with anti-NSE, 59 (52%) had 1-10% positive cells and those of 37 patients (32%) contained no NSE-positive cells. The corresponding figures for Chr A were: 22 patients (19%), 51 patients (45%) and 41 patients (36%), respectively. Forty-four per cent of the patients with more than 10% positive NSE cells responded to chemotherapy (either complete or partial remissions) compared to 17% of the patients with fewer than 10% positive cells (p less than 0.025). The corresponding values for Chr A were 30% responders versus 19% responders (not statistically significant). The median survival for patients with more than 10%, 1-10% or no NSE-positive cells was 262 days, 231 days and 159 days, while, for Chr A it was 245 days, 200 days and 238 days, respectively. The survival curves for both NSE and Chr A according to the various levels of positivity were not significantly different. The presence of neuroendocrine marker in pulmonary adenocarcinoma seems to be associated with increased sensitivity to chemotherapy. | lld:pubmed |
| pubmed-article:1954180 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1954180 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1954180 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1954180 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1954180 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1954180 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1954180 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1954180 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1954180 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1954180 | pubmed:month | May | lld:pubmed |
| pubmed-article:1954180 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:1954180 | pubmed:author | pubmed-author:LarssonL ILI | lld:pubmed |
| pubmed-article:1954180 | pubmed:author | pubmed-author:HansenH HHH | lld:pubmed |
| pubmed-article:1954180 | pubmed:author | pubmed-author:HirschF RFR | lld:pubmed |
| pubmed-article:1954180 | pubmed:author | pubmed-author:SørensenJ BJB | lld:pubmed |
| pubmed-article:1954180 | pubmed:author | pubmed-author:SkovB GBG | lld:pubmed |
| pubmed-article:1954180 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1954180 | pubmed:volume | 2 | lld:pubmed |
| pubmed-article:1954180 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1954180 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1954180 | pubmed:pagination | 355-60 | lld:pubmed |
| pubmed-article:1954180 | pubmed:dateRevised | 2007-4-17 | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:meshHeading | pubmed-meshheading:1954180-... | lld:pubmed |
| pubmed-article:1954180 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1954180 | pubmed:articleTitle | Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. | lld:pubmed |
| pubmed-article:1954180 | pubmed:affiliation | Dept. of Pathology, Rigshospitalet, University of Copenhagen, Denmark. | lld:pubmed |
| pubmed-article:1954180 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1954180 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1954180 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:1954180 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1954180 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1954180 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1954180 | lld:pubmed |
